MX2010011921A - Compuestos para el tratamiento de la hepatitis c. - Google Patents

Compuestos para el tratamiento de la hepatitis c.

Info

Publication number
MX2010011921A
MX2010011921A MX2010011921A MX2010011921A MX2010011921A MX 2010011921 A MX2010011921 A MX 2010011921A MX 2010011921 A MX2010011921 A MX 2010011921A MX 2010011921 A MX2010011921 A MX 2010011921A MX 2010011921 A MX2010011921 A MX 2010011921A
Authority
MX
Mexico
Prior art keywords
alkyl
mmol
solvent
cyclohexyl
methoxy
Prior art date
Application number
MX2010011921A
Other languages
English (en)
Spanish (es)
Inventor
Min Ding
Carl P Bergstrom
Xiaofan Zheng
Scott W Martin
Robert G Gentles
Original Assignee
Squibb Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40786514&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010011921(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Squibb Bristol Myers Co filed Critical Squibb Bristol Myers Co
Publication of MX2010011921A publication Critical patent/MX2010011921A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2010011921A 2008-05-06 2009-05-05 Compuestos para el tratamiento de la hepatitis c. MX2010011921A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5074308P 2008-05-06 2008-05-06
PCT/US2009/042805 WO2009137454A1 (en) 2008-05-06 2009-05-05 7h-indolo[2,1-a] [2] benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
MX2010011921A true MX2010011921A (es) 2010-11-30

Family

ID=40786514

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010011921A MX2010011921A (es) 2008-05-06 2009-05-05 Compuestos para el tratamiento de la hepatitis c.

Country Status (19)

Country Link
US (1) US8133884B2 (cg-RX-API-DMAC7.html)
EP (1) EP2280975B1 (cg-RX-API-DMAC7.html)
JP (1) JP2011520810A (cg-RX-API-DMAC7.html)
KR (1) KR20110015588A (cg-RX-API-DMAC7.html)
CN (1) CN102083834A (cg-RX-API-DMAC7.html)
AR (1) AR071684A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009244409A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0915130A2 (cg-RX-API-DMAC7.html)
CA (1) CA2723683A1 (cg-RX-API-DMAC7.html)
CL (1) CL2009001089A1 (cg-RX-API-DMAC7.html)
CO (1) CO6290645A2 (cg-RX-API-DMAC7.html)
EA (1) EA201001748A1 (cg-RX-API-DMAC7.html)
IL (1) IL208753A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010011921A (cg-RX-API-DMAC7.html)
NZ (1) NZ588556A (cg-RX-API-DMAC7.html)
PE (1) PE20091879A1 (cg-RX-API-DMAC7.html)
TW (1) TW200951135A (cg-RX-API-DMAC7.html)
WO (1) WO2009137454A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201007649B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
ATE531373T1 (de) 2008-03-27 2011-11-15 Bristol Myers Squibb Co Aromatische heterocyclische kondensierte indolobenzadiazepin-hcv-ns5b-inhibitoren
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
WO2012087833A1 (en) 2010-12-22 2012-06-28 Abbott Laboratories Hepatitis c inhibitors and uses thereof
WO2013030750A1 (en) 2011-09-01 2013-03-07 Lupin Limited Antiviral compounds
US9073943B2 (en) 2012-02-10 2015-07-07 Lupin Limited Antiviral compounds with a dibenzooxaheterocycle moiety
EP3091022A3 (en) * 2012-07-18 2016-12-14 Bristol-Myers Squibb Holdings Ireland Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005080399A1 (ja) 2004-02-24 2005-09-01 Japan Tobacco Inc. 4環縮合複素環化合物及びそのhcvポリメラーゼ阻害剤としての利用
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
RU2007119562A (ru) 2004-10-26 2008-12-10 Институто Ди Ричерке Ди Биолоджиа Молеколаре П Анджелетти Спа (It) Тетрациклические производные индолов в качестве противовирусных агентов
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
DE602007006796D1 (de) 2006-05-25 2010-07-08 Bristol Myers Squibb Co Cyclopropyl-fusionierte indolbenzazepin-hcv-ns5b-hemmer
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20090018163A1 (en) 2007-07-11 2009-01-15 Bristol-Myers Squibb Company Substituted Heterocyclic Ethers and Their Use in CNS Disorders
US7652004B2 (en) 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7642251B2 (en) 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8129367B2 (en) 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C

Also Published As

Publication number Publication date
CO6290645A2 (es) 2011-06-20
CA2723683A1 (en) 2009-11-12
WO2009137454A1 (en) 2009-11-12
EP2280975B1 (en) 2014-01-01
US20090280083A1 (en) 2009-11-12
EA201001748A1 (ru) 2011-06-30
CL2009001089A1 (es) 2011-04-29
EP2280975A1 (en) 2011-02-09
AR071684A1 (es) 2010-07-07
NZ588556A (en) 2012-06-29
AU2009244409A1 (en) 2009-11-12
TW200951135A (en) 2009-12-16
IL208753A0 (en) 2010-12-30
KR20110015588A (ko) 2011-02-16
US8133884B2 (en) 2012-03-13
BRPI0915130A2 (pt) 2019-09-24
PE20091879A1 (es) 2009-12-19
ZA201007649B (en) 2012-04-25
JP2011520810A (ja) 2011-07-21
CN102083834A (zh) 2011-06-01

Similar Documents

Publication Publication Date Title
JP5465670B2 (ja) C型肝炎を治療するための化合物
JP5301473B2 (ja) C型肝炎の治療のための化合物
JP5416710B2 (ja) シクロプロピル縮合インドロベンズアゼピンhcvns5b阻害剤
US20080227769A1 (en) Compounds for the Treatment of Hepatitis C
WO2007033175A1 (en) Indolobenzazepine hcv ns5b inhibitors
MX2007001683A (es) Inhibidores de la replicacion del virus de la hepatitis c (vhc).
WO2008112851A1 (en) Cyclopropyl fused indolobenzazepine hcv inhibitors
AU2007211988A1 (en) HCV NS5B inhibitors
WO2011150190A2 (en) Hcv inhibitor compounds and methods of use thereof
EP2121696A1 (en) Compounds for the treatment of hepatitis c
MX2012010216A (es) Compuestos para el tratamiento de hepatitis c.
EP2280975B1 (en) 7h-indolo[2,1-a][2]benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c
US8143243B2 (en) Compounds for the treatment of hepatitis C
EP2396329B1 (en) Compounds for the treatment of hepatitis c
WO2009120650A1 (en) Aromatic heterocyclic fused indolobenzadiazepine hcv ns5b inhibitors

Legal Events

Date Code Title Description
FG Grant or registration